Patients with severe asthma initiated dupilumab and tezepelumab treatment more often than other biologics between 2022 and ...

Dupilumab reduced airway inflammation and mucus burden and enhanced airway volume and flow, which led to better lung function and improved asthma control in patients with moderate to severe type 2 ...

Is DUPIXENT worth it for asthma? Dupixent (dupilumab) is a monoclonal antibody medication that can be used in combination with other drugs to help treat eosinophilic asthma. Dupixent (dupilumab ...

18 months after saying "no" to regular NHS funding for Sanofi and Regeneron's Dupixent (dupilumab) for severe asthma in initial guidance, NICE has now backed the drug. The final appraisal ...

A new study published in the journal of Respiratory Investigation showed that in actual clinical practice, starting a ...

SAN DIEGO — Patients with severe asthma initiated dupilumab and tezepelumab treatment more often than other biologics between 2022 and 2023, according to a poster presented here. As average ...

Dupixent (dupilumab) is a brand-name subcutaneous injection that’s prescribed for atopic dermatitis, asthma, and more. It works to treat those conditions by blocking proteins that cause ...

asthma, CRSwNP, eosinophilic esophagitis (EoE), prurigo nodularis, CSU and COPD in different age populations. More than 1,000,000 patients are being treated with Dupixent globally. 1 Dupilumab is ...

Dupixent approved as the first-ever biologic medicine in Japan for patients with COPDFollowing recent approvals in the EU, China, and the US, ...

Medscape Medical News, March 18, 2025 Dupilumab Boosts Asthma Control and Lung Function In a phase 4 trial, dupilumab effectively reduces airway inflammation and mucus plugging, improving lung ...

In addition to COPD, Dupixent is approved in Japan in certain patients with atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposis (CRSwNP), prurigo nodularis and chronic ...